▮ DFV TERMINAL
--:--:-- UTC SIGN IN
F1 Terminal / LEGN

LEGN — Legend Biotech Corp

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1801198 ·
Last close
$35.48
Market Cap
$6.59B
52W High
$37.50
52W Low
$16.70
ADV30
2,940,083
Next earnings
2026-08-10
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 305,100,000 129,200,000 -49,800,000 -54,300,000 1,596,700,000 646,400,000 629,000,000
Dec 2025 306,377,000 182,918,000 -20,602,000 -30,815,000 1,733,700,000 901,900,000 731,600,000
Sep 2025 272,330,000 157,024,000 -43,452,000 -39,689,000 1,712,948,000 278,893,000 701,688,000
Jun 2025 255,058,000 157,067,000 -21,881,000 -125,380,000 1,689,914,000 266,586,000 654,375,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-100,200,000
Investing CF
$709,600,000
Financing CF
$-300,000
CapEx
$-28,600,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.60
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,958,500,000
Inventory
$32,000,000
Receivables
$250,300,000
ST Investments
$46,700,000
EBIT TTM
$-261,200,000
Pretax Income TTM
$-282,600,000
Interest Exp TTM
$21,400,000
Analysts
16

Yahoo Snapshot (yfinance, live)

Total Revenue
$1,139,000,064
EBITDA
$-125,100,000
Free Cash Flow
$-55,770,000
Enterprise Value
$6,144,748,032
Total Cash
$834,600,000
Total Debt
$389,300,000
Shares Out
185,739,792
Trailing EPS
$-1.38
Book Value
$5.21
ROE
-25.2%
ROA
-5.2%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 1,028,900,000 -136,500,000 -296,800,000 1,733,700,000 731,600,000 — -100,200,000
Dec 2024 627,300,000 -309,500,000 -177,000,000 1,670,200,000 629,600,000 — -144,000,000
Dec 2023 285,100,000 -528,100,000 -518,300,000 1,848,609,000 597,238,000 — -393,300,000
Dec 2022 117,005,000 -455,620,000 -446,349,000 1,330,963,000 586,651,000 — -201,281,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$1.33

Max Pain — expiry 2026-06-18

max pain strike: $27.50 · spot: $33.48 · call oi: 5,452 · put oi: 2,142
Expected Move to 2026-06-18: ±$1.84 (5.50%) — implied range $31.64 – $35.32 · ATM straddle on $32.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
LQDA Liquidia Corp $6.39B $71.80 —
PTCT PTC THERAPEUTICS, INC. $6.37B $76.77 —
MIRM Mirum Pharmaceuticals, Inc. $6.16B $101.00 —
RYTM RHYTHM PHARMACEUTICALS, INC. $6.15B $89.70 —
CNTA Centessa Pharmaceuticals plc $6.15B $39.76 —

News headlines (Yahoo Finance, 1h cache)

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
2026-06-15 12:00 · Yahoo
Legend Biotech (LEGN) Is Up 26.2% After Early In Vivo CAR-T Success in B-Cell Lymphoma
2026-06-04 13:12 · Yahoo
Legend surges on early data for ‘in vivo’ lymphoma cell therapy
2026-06-03 11:57 · Yahoo
Legend Biotech (LEGN) Soars 42% on Promising Cancer Therapy Results
2026-06-03 00:14 · Yahoo
Legend's Cancer-Fighter Notches Elusive 100% Success Rate; What's Next?
2026-06-02 20:30 · Yahoo
ASCO 2026: Mixed SCLC result for Legend’s LB2102, Novartis expedites manufacture
2026-06-02 15:28 · Yahoo
Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)
2026-06-02 13:30 · Yahoo
Legend Biotech CARVYKTI Data And Adoption Trends Meet Depressed Share Price
2026-06-01 21:13 · Yahoo
Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026
2026-06-01 14:00 · Yahoo
Legend Biotech Conference Spotlights CARVYKTI’s Curative Potential, Earlier Use
2026-06-01 02:03 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.
SEC EDGAR filings → · StockAnalysis.com → · OpenInsider →